2020 Q1 Form 10-Q Financial Statement
#000156459020023689 Filed on May 11, 2020
Income Statement
| Concept | 2020 Q1 | 2019 Q1 |
|---|---|---|
| Revenue | $7.152M | $8.629M |
| YoY Change | -17.12% | 48.96% |
| Cost Of Revenue | ||
| YoY Change | ||
| Gross Profit | ||
| YoY Change | ||
| Gross Profit Margin | ||
| Selling, General & Admin | $8.710M | $7.720M |
| YoY Change | 12.82% | 75.06% |
| % of Gross Profit | ||
| Research & Development | $17.62M | $15.18M |
| YoY Change | 16.07% | 16.04% |
| % of Gross Profit | ||
| Depreciation & Amortization | $1.099M | $1.137M |
| YoY Change | -3.34% | -2.15% |
| % of Gross Profit | ||
| Operating Expenses | $17.62M | $22.90M |
| YoY Change | -23.04% | 30.86% |
| Operating Profit | -$14.27M | |
| YoY Change | 21.9% | |
| Interest Expense | -$420.0K | $20.00K |
| YoY Change | -2200.0% | -105.88% |
| % of Operating Profit | ||
| Other Income/Expense, Net | ||
| YoY Change | ||
| Pretax Income | -$19.60M | -$14.25M |
| YoY Change | 37.54% | 18.26% |
| Income Tax | ||
| % Of Pretax Income | ||
| Net Earnings | -$19.60M | -$14.25M |
| YoY Change | 37.51% | 18.3% |
| Net Earnings / Revenue | -273.98% | -165.14% |
| Basic Earnings Per Share | -$0.84 | |
| Diluted Earnings Per Share | -$0.84 | -$623.1K |
| COMMON SHARES | ||
| Basic Shares Outstanding | 23.10M | 22.93M |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2020 Q1 | 2019 Q1 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $115.4M | $170.6M |
| YoY Change | -32.36% | |
| Cash & Equivalents | $43.57M | $26.62M |
| Short-Term Investments | $71.80M | $144.0M |
| Other Short-Term Assets | $3.000M | $2.600M |
| YoY Change | 15.38% | |
| Inventory | ||
| Prepaid Expenses | ||
| Receivables | $9.100M | $3.300M |
| Other Receivables | $0.00 | $0.00 |
| Total Short-Term Assets | $127.5M | $176.5M |
| YoY Change | -27.76% | |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $9.500M | $9.900M |
| YoY Change | -4.04% | |
| Goodwill | ||
| YoY Change | ||
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | $14.20M | $13.70M |
| YoY Change | 3.65% | |
| Other Assets | $2.700M | $2.235M |
| YoY Change | 20.81% | |
| Total Long-Term Assets | $26.40M | $25.96M |
| YoY Change | 1.7% | |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $127.5M | $176.5M |
| Total Long-Term Assets | $26.40M | $25.96M |
| Total Assets | $153.9M | $202.5M |
| YoY Change | -23.98% | |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $5.800M | $3.395M |
| YoY Change | 70.84% | |
| Accrued Expenses | $2.900M | $2.502M |
| YoY Change | 15.91% | |
| Deferred Revenue | $19.02M | |
| YoY Change | ||
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | $0.00 | $5.800M |
| YoY Change | -100.0% | |
| Total Short-Term Liabilities | $32.00M | $31.13M |
| YoY Change | 2.79% | |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $24.20M | $8.500M |
| YoY Change | 184.71% | |
| Other Long-Term Liabilities | $15.60M | $32.10M |
| YoY Change | -51.4% | |
| Total Long-Term Liabilities | $39.80M | $40.60M |
| YoY Change | -1.97% | |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $32.00M | $31.13M |
| Total Long-Term Liabilities | $39.80M | $40.60M |
| Total Liabilities | $71.80M | $71.70M |
| YoY Change | 0.14% | |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$215.3M | -$154.3M |
| YoY Change | 39.58% | |
| Common Stock | $297.4M | $284.9M |
| YoY Change | 4.38% | |
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $82.09M | $130.7M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $153.9M | $202.5M |
| YoY Change | -24.0% |
Cashflow Statement
| Concept | 2020 Q1 | 2019 Q1 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$19.60M | -$14.25M |
| YoY Change | 37.51% | 18.3% |
| Depreciation, Depletion And Amortization | $1.099M | $1.137M |
| YoY Change | -3.34% | -2.15% |
| Cash From Operating Activities | -$18.73M | -$20.15M |
| YoY Change | -7.0% | 34.21% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $763.0K | $276.0K |
| YoY Change | 176.45% | -24.18% |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | $42.40M | -$77.80M |
| YoY Change | -154.5% | |
| Cash From Investing Activities | $41.64M | -$78.08M |
| YoY Change | -153.33% | 21350.27% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | 15.70M | -458.0K |
| YoY Change | -3528.38% | 3171.43% |
| NET CHANGE | ||
| Cash From Operating Activities | -18.73M | -20.15M |
| Cash From Investing Activities | 41.64M | -78.08M |
| Cash From Financing Activities | 15.70M | -458.0K |
| Net Change In Cash | 38.61M | -98.68M |
| YoY Change | -139.12% | 541.29% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$18.73M | -$20.15M |
| Capital Expenditures | $763.0K | $276.0K |
| Free Cash Flow | -$19.50M | -$20.42M |
| YoY Change | -4.52% | 32.83% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2019Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
22865075 | |
| CY2020Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-19595000 | |
| CY2020Q1 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2020Q1 | us-gaap |
Revenue From Related Parties
RevenueFromRelatedParties
|
2813000 | |
| CY2020Q1 | us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
-137000 | |
| CY2019Q1 | us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
103000 | |
| CY2020Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-19732000 | |
| CY2019Q1 | us-gaap |
Revenue From Related Parties
RevenueFromRelatedParties
|
4916000 | |
| CY2020Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
17619000 | |
| CY2020Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
8713000 | |
| CY2019Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
7715000 | |
| CY2019Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-14147000 | |
| CY2020Q1 | us-gaap |
Substantial Doubt About Going Concern Within One Year
SubstantialDoubtAboutGoingConcernWithinOneYear
|
false | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
|
0.7315 | |
| CY2019Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
|
0.7289 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
|
0.7734 | |
| CY2019Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
|
0.7489 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
|
0.0079 | |
| CY2019Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
|
0.0240 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
|
0.0162 | |
| CY2019Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
|
0.0255 | |
| CY2019Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
22895000 | |
| CY2020Q1 | stro |
Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
|
-1056000 | |
| CY2019Q1 | stro |
Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
|
-1160000 | |
| CY2020Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
23197971 | |
| CY2019Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
6017000 | |
| CY2019Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2020Q1 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2020Q1 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2019Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
5584000 | |
| CY2019Q4 | us-gaap |
Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
|
19465000 | |
| CY2019Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
2545000 | |
| CY2019Q4 | us-gaap |
Assets
Assets
|
156370000 | |
| CY2019Q4 | us-gaap |
Restricted Cash Noncurrent
RestrictedCashNoncurrent
|
15000 | |
| CY2019Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2019Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
| CY2019Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2019Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
8629000 | |
| CY2020Q1 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
| CY2019Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
23098969 | |
| CY2020Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
7152000 | |
| CY2019Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2019Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
300000000 | |
| CY2019Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
23098969 | |
| CY2019Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | |
| CY2020Q1 | us-gaap |
Common Stock Value
CommonStockValue
|
23000 | |
| CY2020Q1 | us-gaap |
Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
|
6404000 | |
| CY2019Q4 | us-gaap |
Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
|
1050000 | |
| CY2019Q4 | us-gaap |
Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
|
15609000 | |
| CY2020Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-19595000 | |
| CY2020Q1 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
297374000 | |
| CY2020Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2020Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
300000000 | |
| CY2020Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
23227421 | |
| CY2020Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
23227421 | |
| CY2019Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
23000 | |
| CY2019Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
293346000 | |
| CY2019Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
156370000 | |
| CY2019Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
165000 | |
| CY2019Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-195745000 | |
| CY2019Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
97789000 | |
| CY2019Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
15180000 | |
| CY2020Q1 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | |
| CY2020Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
1099000 | |
| CY2020Q1 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
41000 | |
| CY2020Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-215340000 | |
| CY2020Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
82085000 | |
| CY2020Q1 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
153875000 | |
| CY2020Q1 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
28000 | |
| CY2020Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
2707000 | |
| CY2020Q1 | us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
19000 | |
| CY2019Q1 | us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
-73000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
849000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-1417000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-336000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
476000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
|
-3073000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
|
-3715000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
|
-745000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
|
397000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
|
36000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
|
7000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
2326000 | |
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-18734000 | |
| CY2019Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-20145000 | |
| CY2020Q1 | us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
3600000 | |
| CY2019Q1 | us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
119053000 | |
| CY2020Q1 | stro |
Proceeds From Maturities Of Marketable Securities
ProceedsFromMaturitiesOfMarketableSecurities
|
37500000 | |
| CY2019Q1 | stro |
Proceeds From Maturities Of Marketable Securities
ProceedsFromMaturitiesOfMarketableSecurities
|
37750000 | |
| CY2020Q1 | stro |
Proceeds From Sales Of Marketable Securities
ProceedsFromSalesOfMarketableSecurities
|
8500000 | |
| CY2019Q1 | stro |
Proceeds From Sales Of Marketable Securities
ProceedsFromSalesOfMarketableSecurities
|
3500000 | |
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
41637000 | |
| CY2019Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-78079000 | |
| CY2020Q1 | us-gaap |
Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
|
25000000 | |
| CY2020Q1 | us-gaap |
Repayments Of Debt
RepaymentsOfDebt
|
10000000 | |
| CY2020Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
56000 | |
| CY2020Q1 | us-gaap |
Proceeds From Stock Plans
ProceedsFromStockPlans
|
646000 | |
| CY2019Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-458000 | |
| CY2019Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-98682000 | |
| CY2018Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
125313000 | |
| CY2020Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
43580000 | |
| CY2019Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
26631000 | |
| CY2019Q1 | us-gaap |
Interest Paid Net
InterestPaidNet
|
330000 | |
| CY2019Q1 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
63000 | |
| CY2019Q1 | stro |
Embedded Interest Associated With Program Fees
EmbeddedInterestAssociatedWithProgramFees
|
860000 | |
| CY2020Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-19595000 | |
| CY2019Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-14250000 | |
| CY2019Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
97789000 | |
| CY2020Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
56000 | |
| CY2020Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
82085000 | |
| CY2019Q1 | us-gaap |
Cumulative Effect On Retained Earnings Net Of Tax1
CumulativeEffectOnRetainedEarningsNetOfTax1
|
10327000 | |
| CY2019Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
42000 | |
| CY2019Q1 | us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
671000 | |
| CY2019Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
2286000 | |
| CY2019Q1 | us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
103000 | |
| CY2019Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-14250000 | |
| CY2020Q1 | us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
646000 | |
| CY2020Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
2707000 | |
| CY2020Q1 | stro |
Warrants Issued During Period Value In Connection With Debt Refinancing
WarrantsIssuedDuringPeriodValueInConnectionWithDebtRefinancing
|
619000 | |
| CY2020Q1 | us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
-137000 | |
| CY2019Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
1137000 | |
| CY2019Q1 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
600000 | |
| CY2019Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
2286000 | |
| CY2020Q1 | us-gaap |
Unrealized Gain Loss On Derivatives And Commodity Contracts
UnrealizedGainLossOnDerivativesAndCommodityContracts
|
-7000 | |
| CY2019Q1 | us-gaap |
Unrealized Gain Loss On Derivatives And Commodity Contracts
UnrealizedGainLossOnDerivativesAndCommodityContracts
|
127000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
2781000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
-5302000 | |
| CY2020Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
763000 | |
| CY2019Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
276000 | |
| CY2019Q1 | us-gaap |
Repayments Of Debt
RepaymentsOfDebt
|
500000 | |
| CY2019Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
42000 | |
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
15702000 | |
| CY2020Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
38605000 | |
| CY2019Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
4975000 | |
| CY2020Q1 | us-gaap |
Interest Paid Net
InterestPaidNet
|
134000 | |
| CY2020Q1 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
255000 | |
| CY2020Q1 | stro |
Embedded Interest Associated With Program Fees
EmbeddedInterestAssociatedWithProgramFees
|
600000 | |
| CY2020Q1 | stro |
Warrants Issued To Lenders As Part Of Debt Discount
WarrantsIssuedToLendersAsPartOfDebtDiscount
|
619000 | |
| CY2020Q1 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1. Organization and Principal Activities</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Description of Business </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:3.4%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sutro Biopharma, Inc. (the “Company”), is a clinical stage drug discovery, development and manufacturing company focused on deploying its proprietary integrated cell-free protein synthesis platform, XpressCF®, to create a broad variety of optimally designed, next-generation protein therapeutics initially for cancer and autoimmune disorders. The Company was incorporated on April 21, 2003 and is headquartered in South San Francisco, California. </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company operates in one business segment, the development of biopharmaceutical products. </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Liquidity </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has incurred significant losses and has negative cash flows from operations. As of March 31, 2020, the Company had an accumulated deficit of $215.3 million. Management expects to continue to incur additional substantial losses in the foreseeable future as a result of the Company’s research and development activities and costs to operate as a public company. </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2020, the Company had unrestricted cash, cash equivalents and marketable securities of $129.6 million, which are available to fund future operations. The Company will need to raise additional capital to support the completion of its research and development activities and its operations. </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.4%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company believes that its unrestricted cash, cash equivalents and marketable securities as of March 31, 2020 will be sufficient for the Company to continue for at least one year from the issuance date of its unaudited interim condensed financial statements. </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;"> </p> | |
| CY2020Q1 | dei |
Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
|
2003-04-21 | |
| CY2020Q1 | dei |
Entity Address City Or Town
EntityAddressCityOrTown
|
South San Francisco | |
| CY2020Q1 | dei |
Entity Address State Or Province
EntityAddressStateOrProvince
|
CA | |
| CY2020Q1 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | |
| CY2020Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-215300000 | |
| CY2020Q1 | stro |
Unrestricted Cash Cash Equivalents And Marketable Securities At Carrying Value
UnrestrictedCashCashEquivalentsAndMarketableSecuritiesAtCarryingValue
|
129600000 | |
| CY2020Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
43565000 | |
| CY2019Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
26616000 | |
| CY2020Q1 | us-gaap |
Restricted Cash Noncurrent
RestrictedCashNoncurrent
|
15000 | |
| CY2019Q1 | us-gaap |
Restricted Cash Noncurrent
RestrictedCashNoncurrent
|
15000 | |
| CY2020Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
43580000 | |
| CY2019Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
26631000 | |
| CY2019Q4 | us-gaap |
Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
|
15600000 | |
| CY2020Q1 | us-gaap |
Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
|
48500000 | |
| CY2019Q4 | us-gaap |
Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
|
4500000 | |
| CY2020Q1 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
153000 | |
| CY2019Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
3000 | |
| CY2020Q1 | us-gaap |
Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
|
0 | |
| CY2019Q1 | us-gaap |
Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
|
0 | |
| CY2020Q1 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
127462000 | |
| CY2020Q1 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
181000 | |
| CY2020Q1 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
153000 | |
| CY2020Q1 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
127490000 | |
| CY2019Q4 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
131499000 | |
| CY2019Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
168000 | |
| CY2019Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
3000 | |
| CY2019Q4 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
131664000 | |
| CY2020Q1 | us-gaap |
Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
|
14200000 | |
| CY2020Q1 | us-gaap |
Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
|
22900000 | |
| CY2020Q1 | us-gaap |
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
|
P12M | |
| CY2020Q1 | stro |
Convertible Preferred Stock Warrant Liability Fair Value
ConvertiblePreferredStockWarrantLiabilityFairValue
|
100000 | |
| CY2019Q4 | stro |
Convertible Preferred Stock Warrant Liability Fair Value
ConvertiblePreferredStockWarrantLiabilityFairValue
|
100000 | |
| CY2020Q1 | us-gaap |
Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
|
200000 | |
| CY2019Q4 | us-gaap |
Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
|
400000 | |
| CY2020Q1 | us-gaap |
Interest Expense Debt
InterestExpenseDebt
|
200000 | |
| CY2019Q1 | us-gaap |
Interest Expense Debt
InterestExpenseDebt
|
400000 | |
| CY2020Q1 | us-gaap |
Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
|
0.0809 | |
| CY2019Q1 | us-gaap |
Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
|
0.0890 | |
| CY2020Q1 | us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
86000 | |
| CY2019Q1 | us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
42000 | |
| CY2020Q1 | us-gaap |
Common Stock Voting Rights
CommonStockVotingRights
|
one vote per share | |
| CY2020Q1 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
8693572 | |
| CY2019Q4 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
7357234 | |
| CY2018Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | |
| CY2018Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2019Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2020Q1 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
76000 | |
| CY2019Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
46000 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
4.94 | |
| CY2019Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
5.86 | |
| CY2020Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
2707000 | |
| CY2019Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
2286000 | |
| CY2020Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-19595000 | |
| CY2019Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-14250000 | |
| CY2020Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-19595000 | |
| CY2019Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-14250000 | |
| CY2020Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
23197971 | |
| CY2019Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
22865075 | |
| CY2020Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.84 | |
| CY2019Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.62 | |
| CY2020Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
6065721 | |
| CY2019Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
4411627 |
